Findings

What do systematic reviews say?

4,860 questions · 64,864 findings · 4,913 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 21.4%GRADE not reported 3,491 · 5.4%Very low 16,300 · 25.1%Low 17,338 · 26.7%Moderate 10,900 · 16.8%High 2,966 · 4.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and with the F508del/MF genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

FEV1 % predicted: absolute change from baseline · adults with cystic fibrosis and with the F508del/MF genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

Adverse events · adults with cystic fibrosis and with the F508del/MF genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 76 participants
Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

Time to first pulmonary exacerbation · adults with cystic fibrosis and with the F508del/MF genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Quality of life: total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Skin‐sparing mastectomy vs conventional mastectomy

Overall survival,assessed as time to any death · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer

It is very uncertain whether skin‐sparing mastectomy changes overall survival,assessed as time to any death compared with conventional mastectomy (very low certainty).

1 finding from 1 review

Skin‐sparing mastectomy for the treatment of breast cancer 2023 · Cochrane Headline outcomes only
HR 0.41 [0.17, 1.02]
1306 participants
Very low

Skin‐sparing mastectomy vs conventional mastectomy

Local recurrence‐free survival · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer

It is very uncertain whether skin‐sparing mastectomy changes local recurrence‐free survival compared with conventional mastectomy (very low certainty).

1 finding from 1 review

Skin‐sparing mastectomy for the treatment of breast cancer 2023 · Cochrane Headline outcomes only
HR 0.82 [0.47, 1.42]
5690 participants
Very low

Skin‐sparing mastectomy vs conventional mastectomy

Overall complications,assessed using the number of participants with at least one local or systemic complication · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer

It is very uncertain whether skin‐sparing mastectomy changes overall complications,assessed using the number of participants with… compared with conventional mastectomy (very low certainty).

1 finding from 1 review

Skin‐sparing mastectomy for the treatment of breast cancer 2023 · Cochrane Headline outcomes only
RR 1.55 [0.97, 2.46]
677 participants
Very low

Skin‐sparing mastectomy vs conventional mastectomy

Breast reconstruction loss · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer

It is very uncertain whether skin‐sparing mastectomy changes breast reconstruction loss compared with conventional mastectomy (very low certainty).

1 finding from 1 review

Skin‐sparing mastectomy for the treatment of breast cancer 2023 · Cochrane Headline outcomes only
RR 1.79 [0.31, 10.35]
475 participants
Very low

Skin‐sparing mastectomy vs conventional mastectomy

Skin necrosis · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer

It is very uncertain whether skin‐sparing mastectomy changes skin necrosis compared with conventional mastectomy (very low certainty).

1 finding from 1 review

Skin‐sparing mastectomy for the treatment of breast cancer 2023 · Cochrane Headline outcomes only
RR 1.15 [0.62, 2.12]
677 participants
Very low

Skin‐sparing mastectomy vs conventional mastectomy

Infection · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer

It is very uncertain whether skin‐sparing mastectomy changes infection compared with conventional mastectomy (very low certainty).

1 finding from 1 review

Skin‐sparing mastectomy for the treatment of breast cancer 2023 · Cochrane Headline outcomes only
RR 2.04 [0.03, 142.71]
371 participants
Very low

Skin‐sparing mastectomy vs conventional mastectomy

Hemorrhage · people with a diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer

It is very uncertain whether skin‐sparing mastectomy changes hemorrhage compared with conventional mastectomy (very low certainty).

1 finding from 1 review

Skin‐sparing mastectomy for the treatment of breast cancer 2023 · Cochrane Headline outcomes only
RR 1.23 [0.47, 3.27]
677 participants
Very low

Antidepressants vs placebo

Efficacy as a continuous outcome · adults with cancer and depression

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 511 participants
Very low

Antidepressants vs placebo

Efficacy as a dichotomous outcome · adults with cancer and depression

It is very uncertain whether antidepressants changes efficacy as a dichotomous outcome compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.74 [0.57, 0.96]
7 studies · 662 participants
Very low

Antidepressants vs placebo

Acceptability ‐ total dropouts · adults with cancer and depression

It is very uncertain whether antidepressants changes dropouts due to any cause (acceptability) compared with placebo (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.85 [0.52, 1.38]
9 studies · 479 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a continuous outcome · patients with cancer and depression

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 237 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Efficacy as a dichotomous outcome · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 1.1
2 studies · 199 participants
Very low

Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)

Acceptability ‐ total dropouts · patients with cancer and depression

It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.83 [0.53, 1.3]
3 studies · 237 participants
Very low